Difficulty: Medium
Average Score: 88%
Practice
A 62-year-old woman with mild MS has some mild difficulty with walking. She is interested in becoming more active with walking and is considering walking a 3.1-mile event with her daughter. Which of the following agents may be beneficial in assisting her with improved ambulation?
Correct answer
A
Rationale
The correct answer is A) Dalfampridine. Dalfampridine, also known as Ampyra, is an extended-release potassium channel blocker that can improve walking in patients with multiple sclerosis (MS) by enhancing nerve conduction. It is indicated for individuals with MS who experience walking difficulties. By taking Dalfampridine, the woman may experience improved ambulation, making it a suitable option for her to consider participating in the walking event with her daughter.
Option B) Fingolimod is a disease-modifying drug used to treat relapsing forms of MS by reducing the frequency of MS flare-ups. While it can help with MS management, it does not directly improve ambulation like Dalfampridine does.
Option C) Mitoxantrone is a chemotherapy agent occasionally used in MS to reduce disease activity. However, it is associated with significant side effects and does not specifically target ambulation improvement.
Option D) Prednisone is a corticosteroid that can be used to manage MS exacerbations, but it is not a primary agent for improving ambulation in patients with mild MS.
Educationally, understanding the pharmacological management of MS is crucial for healthcare providers working with patients with this condition. Knowing the specific indications and mechanisms of action of different drugs allows for tailored treatment plans to address individual symptoms and needs effectively. In this case, selecting the appropriate medication like Dalfampridine can significantly impact the patient's quality of life and functional abilities.
Option B) Fingolimod is a disease-modifying drug used to treat relapsing forms of MS by reducing the frequency of MS flare-ups. While it can help with MS management, it does not directly improve ambulation like Dalfampridine does.
Option C) Mitoxantrone is a chemotherapy agent occasionally used in MS to reduce disease activity. However, it is associated with significant side effects and does not specifically target ambulation improvement.
Option D) Prednisone is a corticosteroid that can be used to manage MS exacerbations, but it is not a primary agent for improving ambulation in patients with mild MS.
Educationally, understanding the pharmacological management of MS is crucial for healthcare providers working with patients with this condition. Knowing the specific indications and mechanisms of action of different drugs allows for tailored treatment plans to address individual symptoms and needs effectively. In this case, selecting the appropriate medication like Dalfampridine can significantly impact the patient's quality of life and functional abilities.